PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Go online to PeerView.com/BDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet’s personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this activity, participants will be able to: Effectively engage patients in conversations about sexual health practice, to assess HIV risk factors and support their ability to have healthy sex lives, Develop comprehensive competencies (with a focus on pre-exposure prophylaxis [PrEP] interventions) based on a provider’s individual patient needs, Consider current evidence and individual patient needs/preferences when integrating HIV prevention options (eg, PrEP, post-exposure prophylaxis [PEP], viral suppression, female condoms) into clinical practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among patients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting patients to available resources, support, and assistance, Describe currently available tools that have been shown to significantly reduce the risk of HIV transmission or acquisition

Go online to PeerView.com/XXE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in addiction medicine discusses opioid use disorder in the outpatient setting and overcoming the various barriers to patients receiving medication. Upon completion of this activity, participants should be better able to: Identify barriers to the implementation of medication-assisted treatment (MAT) for patients with opioid use disorder (OUD), Discuss the efficacy of treatment programs that include MAT for the management of OUD, Employ strategies to effectively and safely integrate MAT into the management of patients with OUD, to reduce opioid misuse and improve treatment retention, particularly in the outpatient setting

Go online to PeerView.com/AMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment of cancer has been transformed by the new immune checkpoint inhibitor class of agents that have shown remarkable benefit in many different types of tumors, but they can also cause unusual immune-related adverse effects (irAEs) that can affect any organ system. Expanding use of these immunotherapies in oncology means that emergency medicine professionals can expect to encounter an increasing number of patients experiencing various irAEs in emergency departments. Timely recognition, accurate diagnosis, and effective management of irAEs can ensure that patients derive maximum benefit from these therapies, and emergency nurses have an important role to play in evaluating and triaging these patients. This CNE educational on-demand activity combines lessons on everything emergency nurses need to know about cancer immunotherapies and irAEs with case discussions and practical guidance for keeping patients with cancer safe in the era of immuno-oncology. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-related adverse effects (irAEs), Characterize the presenting symptoms of the spectrum of irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by emergency nurses and other professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for the recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology specialists

Go online to PeerView.com/YKQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts discuss the role of immunotherapy in multimodal management of locally advanced and early-stage lung cancer. Upon completion of this activity, participants should be better able to: Discuss how to harness the immune system in the treatment of cancer, mechanisms of action of immune checkpoint inhibitors, and rationale for use of immunotherapy in locally advanced and earlier stages of lung cancer in the context of other treatment modalities, including chemotherapy, radiotherapy, and surgery, Evaluate key clinical trial data on the efficacy and safety of immune checkpoint inhibitor–based treatment in patients with unresectable stage III NSCLC whose cancer has not progressed following concurrent chemoradiation, Summarize other key clinical trials evaluating immunotherapies and immunotherapy-based combinatorial approaches in earlier stages of lung cancer, and available evidence from these trials, Identify appropriate patients with locally advanced, unresectable NSCLC who are candidates for immunotherapy as part of multimodal therapy for stage III disease, Implement an optimal multimodal treatment plan inclusive of concurrent chemoradiotherapy and consolidation immunotherapy for appropriate patients with stage III NSCLC, considering the latest evidence, indications, recommendations, and patient needs/preferences, Manage overlapping and non-overlapping adverse effects associated with immunotherapy, radiation therapy, and chemotherapy in patients with stage III NSCLC receiving consolidation therapy with a checkpoint inhibitor following chemoradiation

Go online to PeerView.com/FKA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss the pathophysiology of psoriasis, available treatment options, and choosing the best treatment for each patient. A patient also joins the discussion to provide unique perspectives on living with psoriasis and interacting with healthcare providers. Upon completion of this activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with moderate to severe psoriasis, Identify the pathophysiology of psoriasis as it relates to clinically relevant disease mechanisms and novel therapeutic targets, Describe current treatment options for moderate to severe psoriasis in the context of mechanism of action, efficacy, safety, and optimal clinical use, Employ an evidence-based, patient-centered approach to the management of moderate to severe psoriasis that considers quality of life, comorbidities, and prior treatment history

Go online to PeerView.com/YYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of patients with diabetes. Upon completion of this activity, participants should be better able to: Apply current guidelines for the use of GLP-1 RAs in appropriately selected patients with T2DM, Differentiate current and emerging GLP-1 RAs from each other and from other agents used to treat T2DM, Identify GLP-1 RAs indicated for CV risk reduction in patients with T2DM, Implement shared decision-making with patients with T2DM initiating GLP-1 RA therapy

Go online to PeerView.com/MDM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView onDemand activity based on a nurse-led program at the SUNA 2019 uroLogic Conference, experts on modern RCC treatment (including immunotherapies and TKIs) offer valuable, practical insights on the current therapeutic and regulatory landscape in RCC, real-world application of evidence on novel targeted and immunotherapeutic regimens, the importance of counseling patients on therapeutic expectations with immune checkpoint inhibitors and TKIs, and the recognition and management of unique safety issues associated with newer agents in RCC. Upon completion of this activity, participants will be able to: Summarize the latest efficacy and safety findings on novel regimens, including immune checkpoint inhibitors, tyrosine kinase inhibitors, and combination approaches, for management of patients with renal cell carcinoma (RCC), Provide appropriate education and guidance to patients with RCC on available and emerging targeted- and immuno-therapeutic options in different disease settings, Counsel patients with RCC receiving immune checkpoint inhibitors and/or tyrosine kinase inhibitors on appropriate strategies to manage treatment-related complications

Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.

Go online to PeerView.com/AWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in idiopathic pulmonary fibrosis (IPF) discusses key characteristics of high-resolution computed tomography (HRCT) patterns that differentiate usual interstitial pneumonia (UIP) from probable UIP, indeterminate for UIP, and non-IPF; how to decide whether a patient should undergo a lung biopsy; and implementation of new clinical guidelines for diagnosing IPF. Upon completion of this activity, participants should be better able to: Differentiate UIP from probable UIP, indeterminate for UIP, and non-IPF lung disease according to HRCT scanning patterns, Select patients who should undergo a lung biopsy or cellular analysis of broncho-alveolar lavage fluid according to evidence-based guidelines, Implement updated clinical practice guidelines for the diagnosis of IPF.

Go online to PeerView.com/ASM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in primary care, endocrinology, and diabetes education offer insights on providing patient-centered diabetes care and developing individualized treatment plans for patients with type 2 diabetes mellitus (T2DM). Upon completion of this activity, participants should be better able to: Reconcile recommendations offered in evidence-based clinical guidelines focusing on individualized management of type 2 diabetes mellitus (T2DM), Identify and assess patient factors and health status to appropriately individualize glycemic targets and antihyperglycemic therapy in patients with T2DM, Acknowledge the preferred role and placement of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter 2 (SGLT2) inhibitors in current T2DM treatment algorithms.